A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
LM, IMGN901
Class :
Monoclonal antibody/ recombinant/antineoplastic agent
Brand Name :
N/A
Synonyms :
LM, IMGN901
Class :
Monoclonal antibody/ recombinant/antineoplastic agent
Dosage forms& Strengths
Dose Adjustments
The drug is under clinical trials for studying its activity against the treatment of leukemia, multiple myeloma, ovarian cancer, Merkel cell carcinoma, etc.
Dosage forms& Strengths
The drug is under Phase II of clinical trials for studying the safety and efficacy in the treatment of younger generations suffering from recurrent synovial sarcoma or malignant peripheral sheath tumor, recurrent rhabdomyosarcoma, pleuropulmonary blastoma, recurrent neuroblastoma, Wilms tumor.
Refer to adult dosing.
the risk of adverse effects may be increased
the serum levels of abemaciclib may be increased
the serum levels of acenocoumarol may be increased
the serum levels of acetyldigitoxin may be increased
the risk of adverse effects may be increased
the rate of metabolism of albendazole may be reduced
the risk of adverse effects may be increased
the rate of metabolism of alfuzosin may be reduced
the risk of adverse effects may be increased
the serum levels of alprazolam may be increased
the risk of methemoglobinemia may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the therapeutic activity of BCG vaccine may be reduced
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the risk of adverse effects may be increased
the serum levels of Brigatinib may be increased
the risk of adverse effects may be increased
the rate of metabolism of bromotheophylline may be reduced
the rate of metabolism of caffeine may be reduced
the risk of methemoglobinemia may be increased
Actions and spectrum:
Actions:
Antibody-drug conjugate (ADC) lorvotuzumab mertansine combines with a monoclonal antibody against NCAM1 (CD56) with the maytansinoid DM1 tubulin inhibitor.
Spectrum:
It is a novel antineoplastic drug under study for treating leukemia, multiple myeloma, ovarian cancer, Merkel cell carcinoma, etc.
Frequency not defined
Colonic fistula
Nausea
Vomiting
Hyperglycemia
Increase in ALT
Increase in AST
Black Box Warning
No special warnings for the drug are available
Contraindication/Caution:
Contraindication:
Hypersensitivity
Caution: (non-dose limiting toxicity)
Hypokalemia
Lymphopenia
Hyperuricemia
Dehydration
Vomiting
hypophosphatemia
Pregnancy consideration:
USFDA pregnancy category: Safety and efficacy studies are not established
Lactation:
Safety and efficacy studies are not established
Pregnancy category:
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.
Category B: There was a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence, these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology:
Lorvotuzumab mertansine, also referred to as IMGN-901, is a humanized monoclonal antibody conjugated to maytansinoid DM1 through a thiopentanoate linker. It is an anti-NCAM1 (neural cell adhesion molecule 1, CD56, NCAM-1)].
Pharmacodynamics:
Following internalization and binding to CD56 on a cancer cell, the conjugate releases DM1. In approximately 78% of cases of multiple myeloma (MM), CD56 is highly expressed on the surface. In preclinical environments, IMGN901 demonstrated vigorous anti-myeloma activity both in vivo and in vitro, both alone and in combination with authorized medications like lenalidomide. In a different phase I study, IMGN901 was also demonstrated to be effective and well tolerated when used alone in patients with relapsed or relapsed/refractory MM.
Pharmacokinetics:
Data about the pharmacokinetics of lorvotuzumab mertansine is not documented.
Administration:
To be used as advised by the physician
Patient information leaflet
Generic Name: lorvotuzumab mertansine
Why do we use lorvotuzumab mertansine?
Lorvotuzumab mertansine is a recombinant monoclonal antibody and an antineoplastic agent under study for the treatment of leukemia, small-cell lung cancer (SCLC), and multiple myeloma in adults. In children, the drug is being studied for rhabdomyosarcoma, pleuropulmonary blastoma, refractory or relapsed Wilms tumor, synovial sarcoma, etc.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
